MaxCyte, Inc. Result of AGM (9281F)

TIDMMXCT TIDMMXCR

RNS Number : 9281F

MaxCyte, Inc.

31 October 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

Result of AGM

Gaithersburg, MD - 31 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that at its Annual General Meeting held today at 11:00 EDT, all resolutions were duly passed.

For further information, please contact:

 
 MaxCyte Inc. 
 Doug Doerfler, Chief Executive Officer 
  Ron Holtz, Chief Financial Officer       +1 301 944 1660 
 
 
   Nominated Adviser and Broker 
   Panmure Gordon 
 Emma Earl 
  Freddy Crossley 
  Ryan McCarthy 
 
  Corporate Broking 
  James Stearns                            +44 (0) 20 7886 2500 
 
   Financial PR Adviser 
   Consilium Strategic Communications 
 Mary-Jane Elliott                         +44 (0)203 709 5700 
  Chris Welsh                               maxcyte@consilium-comms.com 
  Sukaina Virji

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation(R) Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGBLBDGDDXBGIB

(END) Dow Jones Newswires

October 31, 2018 12:25 ET (16:25 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024